Other Biopharmaceuticals

ASKA Pharmaceutical Holdings Co., Ltd.

4528

4886

3671

AnnJi Pharmaceutical Co., Ltd. participated in the 2026 KDA Conference, presenting advancements in AJ201, a potential first-in-class therapy for Spinal and Bulbar Muscular Atrophy (SBMA). The company shared promising Phase 2 clinical results and unveiled the design for a global Phase 3 trial aimed at evaluating AJ201's efficacy and safety. AnnJi also hosted a Patient & Family Forum to engage with the SBMA community and announced the formation of a Patient Advisory Council to optimize trial design. The company remains committed to addressing the unmet needs of SBMA patients.

MorningStar

ONO Pharmaceutical Co., Ltd.

Softmax Co., Ltd. (Japan)

Empowering the SBMA Community: AnnJi Highlights Patient & Family Forum and Shares AJ201 Scientific Advancement at the 2026 KDA Conference

3401

Teijin Pharma has entered a joint research agreement with Aska Pharmaceutical to co-develop small-molecule drug candidates for gynaecological diseases. The collaboration aims to leverage Teijin's expertise in computer-aided drug design and AI to expedite early-stage drug discovery. Both companies will focus on identifying compounds that interact with specific molecular targets, optimizing them for efficacy and safety. This partnership seeks to improve the quality of life for women with gynaecological conditions, combining Teijin's advanced drug discovery technologies with Aska's clinical expertise.

Pharmaceutical Technology

Teijin Limited

Teijin and Aska Pharmaceutical to co-develop gynaecological drugs

Using the 2 Stage Free Cash Flow to Equity model, ASKA Pharmaceutical Holdings Co., Ltd. (TSE:4886) has a fair value estimate of JP¥2,994, while its current share price is JP¥2,498, indicating it is trading close to its fair value. The analysis suggests that ASKA's peers are trading at a higher discount to fair value. The total equity value is estimated at JP¥85 billion, with a 17% discount compared to the current stock price. The DCF model highlights the importance of future cash flows and discount rates in valuation.

Simplywall

Estimating The Fair Value Of ASKA Pharmaceutical Holdings Co.,Ltd. (TSE:4886)

ASKA Pharmaceutical Holdings Co., Ltd.(4886.JP)

Empowering the SBMA Community: AnnJi Highlights Patient & Family Forum and Shares AJ201 Scientific Advancement at the 2026 KDA Conference

Teijin and Aska Pharmaceutical to co-develop gynaecological drugs

Estimating The Fair Value Of ASKA Pharmaceutical Holdings Co.,Ltd. (TSE:4886)